Neuropsychology of Financial Capacity (NEUROFIN)

March 16, 2023 updated by: Istituto Auxologico Italiano

The present project aims to investigate the financial capacity in patients diagnosed with Parkinson's Disease or parkinsonism, brain tumor (glioma or meningioma) and cerebrovascular lesion (stroke), in order to evaluate the presence and degree of impairment, and the role of some factors as potential predictors of financial incapacity.

The term 'financial capacity' means both operations relating, for example, to asset management or investing money, and activities of daily life such as shopping or using small sums of money; these activities are mediated by different cognitive functions, from numerical and arithmetic skills to decision making. Financial capacity is, in fact, an instrumental activity of daily life (i.e. Instrumental Activity Of Daily Living, I-ADL) whose impairment negatively affects the functional autonomy of the individual, so as to be subject to legal protection.

To assess financial capacity, the Numerical Activities of Daily Living - Financial (NADL-F; Arcara et al., 2017) will be administered, a battery of tests aimed at investigating both financial performance and financial competence according to the most recent neuropsychological models proposed in the literature.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

99

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Italy
    • Lombardia
      • Milan, Lombardia, Italy, 20122
        • Recruiting
        • Istituto Auxologico Italiano IRCCS
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

  • Patients with Parkinson's Disease/parkinsonisms
  • Patients with brain tumor
  • Patients with stroke
  • Healthy controls

Description

Inclusion Criteria:

  • age > 18 years
  • Clinical diagnosis of interest for clinical groups
  • For stroke patients: disease duration > 1 month

Exclusion Criteria:

  • Other brain disorders different from those of interest
  • Sensory-motor deficits that could prevent neuropsychological assessment
  • Language disorders that could prevent neuropsychological assessment
  • Global cognitive impairment as indexed by MoCA < 26 or MMP < 22.85

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Healthy Controls
Behavioral: Neuropsychological tests

Neuropsychological assessment with:

  • NADL-F
  • Frontal Assessment Battery (FAB)
  • functional scales assessing activities of daily living (ADL) and instrumental activities of daily living (I-ADL)
  • Mini-Mental Parkinson (MMP) - For Parkinson's Disease patients
  • Montreal Cognitive Assessment (MoCA) - for brain tumor and stroke patients
Patients with brain tumors
Behavioral: Neuropsychological tests

Neuropsychological assessment with:

  • NADL-F
  • Frontal Assessment Battery (FAB)
  • functional scales assessing activities of daily living (ADL) and instrumental activities of daily living (I-ADL)
  • Mini-Mental Parkinson (MMP) - For Parkinson's Disease patients
  • Montreal Cognitive Assessment (MoCA) - for brain tumor and stroke patients
Patients with Parkinson's Disease/Parkinsonisms
Behavioral: Neuropsychological tests

Neuropsychological assessment with:

  • NADL-F
  • Frontal Assessment Battery (FAB)
  • functional scales assessing activities of daily living (ADL) and instrumental activities of daily living (I-ADL)
  • Mini-Mental Parkinson (MMP) - For Parkinson's Disease patients
  • Montreal Cognitive Assessment (MoCA) - for brain tumor and stroke patients
Patients with ischemic or haemorrhagic stroke
Behavioral: Neuropsychological tests

Neuropsychological assessment with:

  • NADL-F
  • Frontal Assessment Battery (FAB)
  • functional scales assessing activities of daily living (ADL) and instrumental activities of daily living (I-ADL)
  • Mini-Mental Parkinson (MMP) - For Parkinson's Disease patients
  • Montreal Cognitive Assessment (MoCA) - for brain tumor and stroke patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Numerical Activity of Daily Living Financial (NADL-F) in Patients with Parkinson's Disease/Parkinsonisms
Time Frame: At baseline
Assessment of financial capacity; score range=0-62; higher scores indicate higher financial capacities
At baseline
Numerical Activity of Daily Living Financial (NADL-F) in Patients with ischemic or haemorrhagic stroke
Time Frame: At baseline
Assessment of financial capacity; score range=0-62; higher scores indicate higher financial capacities
At baseline
Change from baseline in Numerical Activity of Daily Living - Financial (NADL-F)Patients with brain tumors
Time Frame: At 3 and 12 months follow up
Assessment of financial capacity; score range=0-62; higher scores indicate higher financial capacities
At 3 and 12 months follow up
Montreal Cognitive Assessment (MoCA)
Time Frame: At baseline
Assessment of global cognitive functioning
At baseline
Frontal Assessment Battery (FAB)
Time Frame: At baseline
Assessment of global cognitive functioning
At baseline
Activities of daily living questionnaire (ADL)
Time Frame: At baseline
Assessment of function independence in everyday life
At baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Istituto Auxologico Italiano

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 4, 2021

Primary Completion (Anticipated)

November 30, 2024

Study Completion (Anticipated)

November 30, 2024

Study Registration Dates

First Submitted

March 5, 2023

First Submitted That Met QC Criteria

March 16, 2023

First Posted (Actual)

March 30, 2023

Study Record Updates

Last Update Posted (Actual)

March 30, 2023

Last Update Submitted That Met QC Criteria

March 16, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 25C121

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Neuropsychological tests

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe